Rigel Pharmaceuticals

$3.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.27%) Today

+$0.02 (+0.53%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RIGL and other stocks, options, and ETFs commission-free!

About RIGL

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. The listed name for RIGL is Rigel Pharmaceuticals, Inc. Common Stock.

CEO

Raul R. Rodriguez

Employees

163

Headquarters

South San Francisco, California

Founded

1996

Market Cap

638.75M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.80M

High Today

$3.83

Low Today

$3.71

Open Price

$3.82

Volume

1.88M

52 Week High

$5.24

52 Week Low

$1.23

Collections

Analyst Ratings

86%

of 7 ratings

Buy

86%

Hold

14%

Sell

RIGL Earnings

-$0.14

-$0.05

$0.04

$0.13

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 2, After Hours